OncLive® On Air

In this podcast, experts Joyce O’Shaughnessy, MD; Reshma L. Mahtani, DO; Heather McArthur, MD, MPH; and Paolo Tarantino, MD, PhD; discuss results of recent frontline maintenance trials for patients with HER2-positive (HER2+) metastatic breast cancer (MBC) and their implications for treatment sequencing and patient management.

In this podcast, experts Charles M. Rudin, MD, PhD; Alex A. Adjei, MD, PhD; and Millie Das, MD; discuss the latest treatment advances for extensive-stage small cell lung cancer (ES-SCLC), including how to sequence bispecific T-cell engagers and antibody-drug conjugates and ways to manage adverse events associated with these newer therapies.

In today’s episode Mazyar Shadman, MD, MPH, discussed results from a post hoc indirect comparison that evaluated zanubrutinib (Brukinsa) from phase 3 SEQUOIA trial (NCT03336333) compared with acalabrutinib (Calquence) plus venetoclax (Venclexta) from the phase 3 AMPLIFY trial (NCT03836261) in patients with treatment-naive chronic lymphocytic leukemia (CLL). Dr Shadman is a professor in the Clinical Research Division, medical director of Cellular Immunotherapy, and the Innovators Network Endowed Chair at Fred Hutchinson Cancer Center in Seattle, Washington.
In our exclusive interview, Dr Shadman began with a top-line overview of how the indirect comparison was conducted and the rationale behind it. After discussing the design of the comparison, Dr Shadman then dove into a conversation on the results of the study, in addition to how it will help oncologists and patients alike in the clinic. Finally, Dr Shadman looked to the future of CLL management and underscored what research he would like to see conducted following the comparison and its results.

In this podcast, experts Hope S. Rugo, MD, FASCO; Giuseppe Curigliano, MD, PhD; Paolo Tarantino, MD, PhD; and Alastair Thompson, MD, MBChB, BSc (Hons), FRCS (Ed), FACS; discuss and debate recently published results of pivotal clinical trials in early-stage, HER2-positive breast cancer and their implications for patient care.

In this podcast, experts Patrick I. Borgen, MD; Don S. Dizon, MD, FACP, FASCO; Kevin S. Hughes, MD, FACS; and Banu Arun, MD, FASCO; discuss how genetic testing drives breast cancer management from screening and surgical decisions to targeted systemic therapies.